Efficacy of Oral Acetaminophen and Intravenous Chlorpheniramine Maleate versus Placebo to Prevent Red Cell Transfusion Reactions in Children and Adolescent with Thalassemia: A Prospective, Randomized, Double-Blind Controlled Trial

Table 1

Patients’ demographic data.

	Active drugs	Placebo	p-value
	(N=73)	(N=74)
Gender
Male	37(50.7)	45(60.8)	0.216
Female	36(49.3)	29(39.2)
Types of Thalassemia
ß thal/ß thal	12(16.4)	7(9.5)	0.353
ß thal/Hb E	49(67.1)	50(67.5)
AE Bart disease	6(8.2)	10(13.5)
Hb H with CS	6(8.2)	7(9.5)
RBC products
LPRC	49(67.1)	50(67.6)	0.954
LDPRC	24(32.9)	24(32.4)
Weight (kg)
Mean±SD	37.7±15.81	33.45±15.07	0.138
Min-Max	10.3-62.3	10.7-61.5
Age (years)
Mean±SD	12.49±4.84	11.32±4.72	0.097
Min-Max	1.58-18.5	1.5-21.17
Age at diagnosis (months)
Mean±SD	24.93±23.84	25.08±24.36	0.970
Min-Max	0.0-87.0	0.0-122

Note: Data were shown as number (%), mean±SD, min-max; p values were analyzed by Chi-square test for categorical data and independent sample t-test for continuous data. p<0.05 is statistically significant.
Abbreviations. ß thal/ß thal: homozygous beta thalassemia; ß thal/HbE: beta thalassemia/hemoglobin E; Hb H with CS: hemoglobin H disease with constant spring; RBC: red blood cell; LPRC: leukocyte poor packed red cell; LDPRC: leukocyte depleted packed red cell.